IRIS
GIULIANI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.033
EU - Europa 6.573
AS - Asia 3.843
AF - Africa 97
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 4
SA - Sud America 3
Totale 18.571
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.886
CN - Cina 2.682
IE - Irlanda 1.611
SE - Svezia 1.483
FI - Finlandia 1.029
IT - Italia 706
DE - Germania 645
UA - Ucraina 623
SG - Singapore 576
TR - Turchia 458
CA - Canada 145
GB - Regno Unito 123
CI - Costa d'Avorio 82
IN - India 79
AT - Austria 73
RO - Romania 65
BE - Belgio 55
CZ - Repubblica Ceca 46
FR - Francia 36
NL - Olanda 24
EU - Europa 18
IR - Iran 17
ES - Italia 8
HK - Hong Kong 8
BG - Bulgaria 7
IL - Israele 6
NG - Nigeria 5
RU - Federazione Russa 5
AE - Emirati Arabi Uniti 4
LU - Lussemburgo 4
PL - Polonia 4
SC - Seychelles 4
AU - Australia 3
CH - Svizzera 3
CM - Camerun 3
DK - Danimarca 3
MD - Moldavia 3
TW - Taiwan 3
HR - Croazia 2
JP - Giappone 2
KH - Cambogia 2
MA - Marocco 2
NO - Norvegia 2
PK - Pakistan 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SM - San Marino 2
AL - Albania 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BR - Brasile 1
BZ - Belize 1
CO - Colombia 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
HU - Ungheria 1
KZ - Kazakistan 1
LT - Lituania 1
MX - Messico 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PS - Palestinian Territory 1
Totale 18.571
Salva come PNG Salva come JPEG
Città #
Chandler 1.645
Dublin 1.605
Jacksonville 758
Beijing 627
Ashburn 597
Boardman 435
Nanjing 406
Izmir 404
Dearborn 382
Singapore 365
Ann Arbor 346
Parma 327
Princeton 323
Shanghai 302
San Mateo 233
Wilmington 186
Shenyang 158
New York 155
Kunming 143
Nanchang 135
Toronto 121
Düsseldorf 114
Helsinki 109
Hebei 105
Jinan 102
Des Moines 87
Hefei 87
Abidjan 82
Jiaxing 78
Bremen 74
Tianjin 72
Vienna 72
Los Angeles 63
Seattle 63
Brussels 55
Changsha 55
Woodbridge 54
Kocaeli 52
Santa Clara 51
Hangzhou 43
Focsani 39
Pune 39
Brno 37
Norwalk 37
Dallas 33
Grafing 29
Zhengzhou 28
Guangzhou 26
Houston 26
Milan 25
Fremont 21
Mestre 21
Ningbo 20
Augusta 18
Chengdu 17
Taizhou 17
Borås 16
Fairfield 16
Haikou 16
Munich 16
Lanzhou 15
Leawood 15
Rockville 15
Washington 15
Phoenix 14
Redmond 14
Amsterdam 13
Fuzhou 13
Bologna 12
Cambridge 12
London 12
Timisoara 12
Wuhan 12
Chongqing 11
Modena 11
Monmouth Junction 11
Taiyuan 11
Edinburgh 10
Palermo 10
Rome 10
Trezzano Sul Naviglio 10
Jesi 9
Rho 9
Ottawa 8
Torino 8
Xian 8
Ahmedabad 7
Auburn Hills 7
Sofia 7
Central 6
Chicago 6
Madrid 6
Nerviano 6
Redwood City 6
Romainville 6
Savignano sul Rubicone 6
Southend 6
St Louis 6
Ardabil 5
Lagos 5
Totale 11.953
Salva come PNG Salva come JPEG
Nome #
Angiopoietin-1 and Osteopontin Expression by CD138+ Myeloma Cells Rather Than VEGF and CD45 Correlates with Bone Marrow Angiogenesis in Multiple Myeloma Patients at the Diagnosis 114
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 103
Are the Myeloma bone microevironment cells tumoral or not? 102
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia 101
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 100
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 100
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 99
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 96
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 94
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: potential relationship with myeloma-induced angiogenesis 93
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 93
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 93
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 92
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 92
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 92
Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage 90
Chemokine receptors CXCR3 and CXCR4 expression in B cell and plasma cell malignancy 89
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 88
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 88
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 87
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 87
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 86
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 85
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 84
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 84
Novel targets for the treatment of relapsing multiple myeloma 83
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 82
Modulation of non canonical wnt5a/ror2 signaling pathway in human mesenchymal cells increases osteogenic differentiation counterbalancing the effect of myeloma cells 82
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 82
Angiopoietins expression by human myeloma cells 81
Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking 80
Possible targets to treat myeloma-related osteoclastogenesis 80
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 80
Analysis of lineage involvment in Philadelphia chromosome positive acute lymphoblastic leukaemia 79
Oncolytic virotherapy and microenvironment in multiple myeloma 79
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation 78
Bisphosphonates inhibit IL-6 production by human osteoblast-like cells 78
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 78
The Proteasome and Myeloma-Associated Bone Disease 78
Angiopoietin-1 and osteopontin expression by CD138+myeloma cells rather than VEGF and CD45 correlates with bone marrow angiogenesis in Multiple Myeloma patients at the diagnosis. 78
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma 78
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 78
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 78
Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo 77
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 77
Bone Marrow Remodelling and Topographic Redistribution of CD34 Positive Progenitors Characterize the Progression of Myelodysplastic Syndromes and Their Evolution to AML 77
(2S,4R)-4-fluoroglutamine is converted into (2S,4R)-4-fluoroglutamate by glutaminase activity and may be exploited as a PET tracer in glutamine-addicted cancers 77
Angiogenic switch in multiple myeloma patients 76
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 76
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 76
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 76
Do human myeloma cells directly produce basic FGF? 76
Functional consequences of low activity of transport system a for neutral amino acids in human bone marrow mesenchymal stem cells 76
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation 75
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 75
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 75
The activation of wnt5a-mediated non canonical wnt signaling in human bone marrow osteoprogenitor cells increases osteoblastogenesis and counterbalances the inhibitory effect of myeloma cells on ror2/fzd5 expression 75
Bone microenvironment cells show a different pattern of gene expression profiling in relationship with the presence of osteolytic bone lesions in Multiple Myeloma patients 75
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2 75
A simplified sars-cov-2 pseudovirus neutralization assay 75
Angiogenic properties of human myeloma cells: role of angiopoietin system 74
Macrophage inflammatory protein (MIP)-3 alpha/CCL20 and its receptor CCR6 are overexpressed in the bone microenvironment and involved in osteoclast formation in multiple myeloma patients. 74
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 73
Angiopoietin-1 and myeloma-induced angiogenesis 73
Expression and role of chemokine receptor CXCR3 in multiple myeloma 73
5-HT3 serotonergic receptor mediation of hypoglycemia-induced arginine-vasopressin but not oxytocin secretion in normal men. 73
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 73
Ectopic production of osteopontin by human myeloma cells and its involvement in myeloma induced angiogenesis 73
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease 73
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 73
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells 73
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 72
Pan-aurora kinase inhibitor MK-0457 synergistically potentiates Apo2l/TRAIL cytotoxicity in Multiple Mieloma cells sensitive and resistant to bortezomib 72
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 72
Addition of Bortezomib to High Dose Melphalan As Conditioning Regimen for Autologous Stem Cell Transplantation Improves the Response Rate in Newly Diagnosed Multiple Myeloma Patients 72
A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis 72
[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma 72
Osteopontin is produced by human multiple myeloma cells 71
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma 71
Bone marrow monocyte / macrophage derived activin a mediates the osteoclastogenic effects of IL-3 in myeloma 71
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. 70
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment 70
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 70
Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes 69
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 69
CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment 69
GPNA inhibits the sodium-independent transport system l for neutral amino acids 69
Autologous bone marrow transplantation in acute myeloid leukemia: a single center experience 69
A translocation t(4;13)(q21;q14) as single clonal chromosomal abnormality in a parathyroid adenoma 69
Effects of hematin and Mössbauer gamma-radiation on human osteosarcoma cell lines 69
A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome 68
Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma 68
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 68
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 68
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis 67
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 67
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 67
Effect of residual endogenous insulin secretion on the abnormal oxytocin response to hypoglycemia in insulin-dependent diabetics. 67
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 67
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 67
Totale 7.870
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.732
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.732
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.032 0 0 159 29 203 309 340 70 255 373 102 192
2020/20211.687 77 171 139 18 244 24 144 47 377 87 292 67
2021/20221.590 31 23 26 110 37 57 199 202 77 145 128 555
2022/20236.260 724 647 387 452 535 671 158 400 1.960 74 187 65
2023/20242.283 110 237 55 58 191 623 195 163 54 126 152 319
2024/2025919 118 403 398 0 0 0 0 0 0 0 0 0
Totale 18.995